Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vaccine trial begins for deadly elephant virus
Image (C) Shutterstock. 'Indali cools off the water, portraying fun and playfulness' - Chester Zoo.

Chester Zoo and the University of Surrey are collaborating on the trial. 

A vaccine trial for elephant endotheliotrophic herpesvirus (EEHV) has begun, as reported by BBC News.

Chester Zoo, in collaboration with scientists at the University of Surrey, has begun the process of trialling a vaccine for the deadly virus, which has killed seven of the zoo's Asian elephant calves. 

Formally characterised in 1999 by researchers at the Smithsonian Zoo, the virus has a mortality rate of up to 85 per cent, and by the time symptoms appear, it it often too late to intervene. 

Elephant keeper at Chester Zoo, Katie Morrison, told BBC News: "We've lost elephants usually between the ages of 18 months and three years," Katie explains. 

"When we see symptoms - lethargy, mouth lesions - it's usually too late. It's so tough - you do everything you can, and it's not enough.” 

The virus is believed to be passed from the older elephants to the calves, potentially when a calf is being weaned, when the antibodies from the mother's milk decline. Although there is still much unknown about the virus. 

Professor Falko Steinbach, from the University of Surrey, told BBC News: “We know it's almost impossible to prevent infection - we're trying to prevent serious disease and death.

“Our aim is to give them a prime before infection, so the elephant's immune system knows the virus and is on the front foot.

"We're using established, safe processes, and it's important to move ahead with a trial in elephants, because there is no other animal we can test this in."

Great progress has already been made by the team, with tests and blood donations from the herd able to diagnose the virus before symptoms appear. This success was demonstrated when Indali, a five-year old Asian elephant at Chester Zoo, tested positive for the virus.

Indali underwent extensive treatment with anti-virals, immune booster and blood plasma transfusions, and she recovered – the only calf to do so at Chester Zoo since 2010. 

As the BBC has reported, Professor Steinbach is hopeful that significant progress will be made towards a vaccine within five years' time. 

 

Image (C) Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.